A carregar...
Association of response endpoints with survival outcomes in multiple myeloma
Since the introduction of the proteasome inhibitor bortezomib and the immunomodulatory drugs (IMiDs) thalidomide and lenalidomide, more patients with multiple myeloma are achieving deep, durable responses and disease control, and are living longer. These improvements have afforded more robust analys...
Na minha lista:
| Main Authors: | , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Nature Publishing Group
2014
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3918869/ https://ncbi.nlm.nih.gov/pubmed/23868105 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/leu.2013.220 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|